Study proves accuracy of MTWA non-invasive test in identifying patients at risk of arrhythmic events and SCD

Cambridge Heart, Inc. (OTCBB- CAMH - News), today announced that results of a clinical study presented at the 29th Annual Scientific Meeting of the Belgian Society of Cardiology in Brussels, Belgium, reinforce the value of the Microvolt T-wave Alternans (MTWA) as an accurate non-invasive test to identify patients at risk of arrhythmic events and sudden cardiac death (SCD).

“Results show that Microvolt T-wave Alternans is that test.”

The study, conducted at Jolimont Hospital in Haine Saint Paul, Belgium, prospectively evaluated MTWA in 73 consecutive patients who met criteria for implantable cardioverter defibrillator implantation for primary prevention of SCD.

At a mean follow-up time of 39 months, the incidence of arrhythmic events in patients with an abnormal MTWA test was 7.6 times that for patients who tested negative. Sudden cardiac death was 4.8 times more common in those with an abnormal MTWA result.

“The aim of the study was to find a test with a very good predictive value in terms of life-threatening arrhythmic events,” said Dr. Antoine de Meester, lead author of the study. “Results show that Microvolt T-wave Alternans is that test.”

“These results further confirm the value of MTWA as a predictor of sudden cardiac death in the primary prevention population,” said Dr. Ali Haghighi-Mood, President and Chief Executive Officer of Cambridge Heart, Inc. “This new data is a significant contribution to the well-established body of literature which supports the use of MTWA for risk stratification.”